Vertical / Trigen was a specialty pharmaceutical company with $42.3 million in revenue engaged in the development, marketing, and distribution prescription pharmaceuticals in the United States. Vertical, the segment of the company focused on branded pharmaceuticals, specialized in women’s health, pain management, and respiratory and allergy medications. Trigen, the generic pharmaceutical arm, marketed over 70 unique formulations in an expanding array of categories including prenatal, hematinic supplements, and cough/cold.
Applied Economics ran a sell-side process for Vertical/Trigen and marketed the company to primarily healthcare/pharma private equity firms. Applied Economics effectively demonstrated the company’s existing product footprint and development pipeline could be leveraged in combination with product acquisitions and licensing opportunities to create attractive financial results.
After initial indications of value were received, AE was able to successfully negotiate a 70% increase in transaction value. The owners were able to achieve partial liquidity, fund growth, and participate in the continued upside of the business.